Vernalis Research represents the research activities of Vernalis plc. With a team experienced in fragment- and structure-based drug discovery since 1997, Vernalis Research has been committed to growing its external research collaborations. External endorsement of its discovery capabilities comes from major pharma companies around the world and includes Novartis, Servier, GSK, Lundbeck, Genentech, Asahi Kasei Pharma and Daiichi Sankyo. Our strengths are in developing and applying the most appropriate fragment- and structure-based methods to work with our partners to solve problems in drug discovery.
The team has generated five development candidates in the past six years and cell active lead compounds against an additional nine targets, with the most recent successes being compounds entering Phase I for Mcl-1 and Bcl-2.
For further information visit us at www.vernalis-research.com.